Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfront

June 1, 2026 06:43 AM EDTUpdated 12:22 PM DealsR&D Lil­ly en­ters GLP-2 space in deal with Ko­re­a's Han­mi, al­so forges dis­cov­ery pact with Chi­na's Hais­co Reynald Castaneda Deputy Editor Eli Lil­ly, which has made bil­lions off the suc­cess of its GLP-1 drugs, is now mak­ing a play for GLP-2s through a li­cens­ing deal with … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER